BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 10213229)

  • 21. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.
    Danks MK; Yoon KJ; Bush RA; Remack JS; Wierdl M; Tsurkan L; Kim SU; Garcia E; Metz MZ; Najbauer J; Potter PM; Aboody KS
    Cancer Res; 2007 Jan; 67(1):22-5. PubMed ID: 17210679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.
    Oosterhoff D; Witlox MA; van Beusechem VW; Haisma HJ; Schaap GR; Bras J; Kruyt FA; Molenaar B; Boven E; Wuisman PI; Pinedo HM; Gerritsen WR
    Mol Cancer Ther; 2003 Aug; 2(8):765-71. PubMed ID: 12939466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme.
    Potter PM; Wolverton JS; Morton CL; Wierdl M; Danks MK
    Cancer Res; 1998 Aug; 58(16):3627-32. PubMed ID: 9721871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
    Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
    Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
    Jansen WJ; Zwart B; Hulscher ST; Giaccone G; Pinedo HM; Boven E
    Int J Cancer; 1997 Jan; 70(3):335-40. PubMed ID: 9033637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.
    Slatter JG; Su P; Sams JP; Schaaf LJ; Wienkers LC
    Drug Metab Dispos; 1997 Oct; 25(10):1157-64. PubMed ID: 9321519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase.
    Satoh T; Hosokawa M; Atsumi R; Suzuki W; Hakusui H; Nagai E
    Biol Pharm Bull; 1994 May; 17(5):662-4. PubMed ID: 7920428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
    Yoon KJ; Qi J; Remack JS; Virga KG; Hatfield MJ; Potter PM; Lee RE; Danks MK
    Mol Cancer Ther; 2006 Jun; 5(6):1577-84. PubMed ID: 16818517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.
    Stubdal H; Perin N; Lemmon M; Holman P; Bauzon M; Potter PM; Danks MK; Fattaey A; Dubensky T; Johnson L
    Cancer Res; 2003 Oct; 63(20):6900-8. PubMed ID: 14583489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53-mediated regulation of expression of a rabbit liver carboxylesterase confers sensitivity to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11).
    Wierdl M; Morton CL; Harris LC; Danks MK; Schuetz JD; Potter PM
    J Pharmacol Exp Ther; 2003 Feb; 304(2):699-705. PubMed ID: 12538824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.
    Wierdl M; Wall A; Morton CL; Sampath J; Danks MK; Schuetz JD; Potter PM
    Mol Pharmacol; 2003 Aug; 64(2):279-88. PubMed ID: 12869632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
    Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.
    Yoon KJ; Hyatt JL; Morton CL; Lee RE; Potter PM; Danks MK
    Mol Cancer Ther; 2004 Aug; 3(8):903-9. PubMed ID: 15299073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA.
    Kojima A; Hackett NR; Crystal RG
    Cancer Res; 1998 Oct; 58(19):4368-74. PubMed ID: 9766666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).
    Matzow T; Cowen RL; Williams KJ; Telfer BA; Flint PJ; Southgate TD; Saunders MP
    J Gene Med; 2007 Apr; 9(4):244-52. PubMed ID: 17397102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
    Harel M; Hyatt JL; Brumshtein B; Morton CL; Yoon KJ; Wadkins RM; Silman I; Sussman JL; Potter PM
    Mol Pharmacol; 2005 Jun; 67(6):1874-81. PubMed ID: 15772291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.
    Pawlik CA; Iyengar RV; Krull EJ; Mason SE; Khanna R; Harris LC; Potter PM; Danks MK; Guichard SM
    Mol Ther; 2000 May; 1(5 Pt 1):457-63. PubMed ID: 10933967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.
    Hyatt JL; Tsurkan L; Wierdl M; Edwards CC; Danks MK; Potter PM
    Mol Cancer Ther; 2006 Sep; 5(9):2281-8. PubMed ID: 16985062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a model.
    Wierdl M; Morton CL; Nguyen NK; Redinbo MR; Potter PM
    Biochemistry; 2004 Feb; 43(7):1874-82. PubMed ID: 14967028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.